High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
SharkNinja (NYSE:SN) reported second-quarter 2026 results marked by accelerating sales growth, higher adjusted earnings and a raised full-year outlook, as the company cited broad demand across domestic and international markets, product categories and sales channels. Net sales increased 22.2% year
Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices and use of patient data. The company addressed the FTC action by outlining its position on how it handles telehealth consultations and consumer information, aiming to reassure users and investors. The lawsuit raises questions about regulatory risk for telehealth providers and how patient data is collected, stored, and used across the...
CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the lowest sticker price in the ...
Hims & Hers Health (HIMS) just introduced an AI powered care experience for Hers weight loss members, including a connected smart scale and app based coaching, giving investors fresh information on its digital health approach. See our latest analysis for Hims & Hers Health. The AI powered weight loss rollout comes at a time when Hims & Hers Health has experienced sharp swings in sentiment, with the share price up 6.51% on the day and 13.76% over seven days, yet down 12.42% over 30 days and...
HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.
Claritev Corporation (CTEV) delivered earnings and revenue surprises of +14.88% and +4.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CareCloud (CCLD) delivered earnings and revenue surprises of -14.29% and -0.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments (NASDAQ:CLOV) reported second-quarter results that showed continued Medicare Advantage membership growth alongside profitability, while raising its full-year 2026 outlook across its key financial measures. Chief Executive Officer Andrew Toy said the company views its Clove
Hims & Hers Health, Inc. (HIMS) closed at $31.65 in the latest trading session, marking a -1.59% move from the prior day.
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
In the past 12 months, the stock has nosedived more than 50%.
Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?
Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”
The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.
The FTC has filed a lawsuit against Hims & Hers Health alleging improper sharing of sensitive health data with advertising platforms and deceptive billing practices. Hims & Hers Health has publicly rejected the allegations and issued a formal response defending its data and billing practices. This action represents a new phase of regulatory scrutiny for NYSE:HIMS that investors are assessing alongside the company’s broader telehealth business. Hims & Hers Health, traded on the NYSE under...
Telehealth platform disclosed users' "most private" health info and locked consumers into subscriptions, regulators allege.
The agency alleges the telehealth company shared sensitive health data with Meta and Snap while deceiving users about charges and cancellations
According to the suit, Hims & Hers shared lists of certain customers, and the actions of visitors on its website, with advertisers such as Meta and Snap, even though it claimed its service maintains consumers’ privacy.
(Updates with Hims' official statement in the third paragraph.) Hims & Hers Health (HIMS) is bein
The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
